Research On Biological Assets Accounting Treatment Of Kangmei Pharmaceutical

In China's national economy,the pharmaceutical industry has always played a relatively important role,people's health and quality of life is inseparable from the pharmaceutical industry.The state has always attached great importance to the development of traditional Chinese medicine.The national health commission has actively implemented the decisions and arrangements of the central government and strengthened the construction and planning of a policy system for traditional Chinese medicine in the formulation of policies on traditional Chinese medicine,so that the role of the traditional Chinese medicine industry can be actively played and the development of traditional Chinese medicine can be promoted.With the further expansion and development of pharmaceutical enterprises,many enterprises make use of biological assets,a special asset,to carry out illegal operations.In this paper,kangmei pharmaceutical co.,ltd.in the pharmaceutical industry is selected as a case study to analyze the problems existing in its biological assets accounting treatment,and make corresponding suggestions according to specific problems.This paper is divided into seven chapters.The first chapter is the introduction,which discusses the background conditions and significance of this research,gives a general description of the research methods and research contents,and summarizes the research results of domestic and foreign scholars.The second chapter introduces the definition of biological assets and relevant accounting standards at home and abroad.The third chapter is the analysis of the current situation of the accounting treatment of biological assets.By analyzing the annual reports of 66 domestic pharmaceutical enterprises in 2017 and 2018,the status quo of their recognition,initial measurement and subsequent measurement of biological assets is understood.According to the contents disclosed in the annual reports,the current problems in the accounting treatment of biological assets in the industry are pointed out.Chapter four introduces the specific situation and company profile of Kangmei Pharmaceutical bio-assets and reviews the cases of its financial fraud using bio-assets.The fifth chapter analyzes the kangmei Pharmaceutical case,first describes the current measurement status of the biological assets of Kangmei Pharmaceutical,the method of depreciation,and the problem of impairment provision;Then,according to the problems in the accounting treatment of the biological assets of Kangmei Pharmaceutical,the reasons for these problems are found to be due to the high loss of the biological assets of Kangmei Pharmaceutical,difficult valuation,and difficult to find signs of impairment,and the enterprise's information disclosure is insufficient,untrue,and not timely.Chapter six is the Suggestions,and the specific Suggestions are divided into three parts:(1)the Suggestions on accounting treatment of biological assets;(2)Suggestions on information disclosure of biological assets;(3)Suggestions on the effective implementation of the safeguard criteria.Chapter seven is the summary of the full text and the shortcomings of the discussion.